TU Dresden


For a world without type 1 diabetes: The POInT study (Type 1 diabetes prevention program)

The initiative "Global Platform for the Prevention of Autoimmune Diabetes (GPPAD), brings together 30 years of genetic and immunological research by cooperating scientists from various European countries. The result is one of the largest initiatives for the early prevention of type 1 diabetes," explains Professor Dr. Ezio Bonifacio, GPPAD co-founder. GPPAD is supported by the US-American Leona M. and Harry B. Helmsley Charitable Trust. GPPAD aims at the early detection of an increased risk of type 1 diabetes and the primary prevention of beta cell autoimmunity and these metabolic diseases for Europe.

Picture © CRTD

Freder1k and POInT

Type 1 diabetes is an autoimmune disease based on the destruction of insulin-producing beta cells in the pancreas by the body's immune system. A new genetic risk score (Bonifacio et al., 2018) allows children with a 10% risk of developing pre-symptomatic type 1 diabetes to be identified soon after birth. This screening has been possible in the Freder1k study since September 2016, in which 330,000 newborns and infants up to the age of 4 months are to be tested for an increased risk of diabetes across Europe. Since February 2018, children at increased risk can participate in the POInT (Primary Oral Insulin Trial) study, which is designed to prevent beta cell autoimmunity and type 1 diabetes by treating them with oral insulin. Children aged 4 to 7 months are included in the POInT study. POInT is an international, randomized, controlled phase IIb study with 1040 planned participating children.

Freder1k and POInT study: Hand in hand against type 1 diabetes in children

Further information is available at:




Project leader

Dr. Angela Hommel
+49 (0)351 458 82250

The Freder1k/POInT study in Saxony is run by Dr. Angela Hommel. It includes Prof. E. Bonifacio, Prof. R. Berner, Prof. U. Ceglarek (Leipzig), Dr. P. Delivani, Dr. G. Gemulla, M. Gottschalk, S. Heinke, S. Kowal, F. Lander, Dr. K. Nitzsche, B. Schlee, Dr. M. Stopsack, Prof. P. Wimberger, M.-.L. Zielmann, N. Zubizarreta.

Selected publications

Bonifacio E, Beyerlein A, Hippich M, Winkler C, Vehik K, Weedon MN, Laimighofer M, Hattersley AT, Krumsiek J, Frohnert BI, Steck AK, Hagopian WA, Krischer JP, Lernmark Å, Rewers MJ, She JX, Toppari J, Akolkar B, Oram RA, Rich SS, Ziegler AG; and TEDDY Study Group. Genetic scores to stratify risk of developing multiple islet autoantibodies and type 1 diabetes: A prospective study in children. Plos Med 2018 Apr; 15(4):e1002548.

Hommel A, Haupt F, Delivani P, Winkler C, Stopsack M, Wimberger P, Nitzsche K, Heinke S, Naeke A, Ceglarek U, Thiery J, Bergert R, Stadthaus D, Groeger K, Heubner G, Schramm U, Dziambor U, Zirkel A, Kiess W, Mueller I, Lange K, Berner R, Bonifacio E, Ziegler AG; and the Freder1k Study Group. Screening for Type 1 Diabetes Risk in Newborns: The Freder1k Pilot Study in Saxony. Horm Metab Res. 2018 Jan; 50(1):44-49.

Ziegler AG, Danne T, Dunger DB, Berner R, Puff R, Kiess W, Agiostratidou G, Todd JA, Bonifacio E. Primary prevention of beta-cell autoimmunity and type 1 diabetes - The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) perspectives. Mol Metab. 2016 Feb; 5(4):255-262.

Bonifacio E, Ziegler AG, Klingensmith G, Schober E, Bingley PJ, Rottenkolber M, Theil A, Eugster A, Puff R, Peplow C, Buettner F, Lange K, Hasford J, Achenbach P, Pre-POINT Study Group. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. JAMA 2015 Apr; 313(15):1541-1549.

An initiative of